Lanean...
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). Here, we report on a post hoc subgroup analysis of tha...
Gorde:
Argitaratua izan da: | Cancer Res Treat |
---|---|
Egile Nagusiak: | , , , , , , , , , |
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
Korean Cancer Association
2016
|
Gaiak: | |
Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4843755/ https://ncbi.nlm.nih.gov/pubmed/26511807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2015.135 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|